FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
RAUSCH CARL W
  2. Issuer Name and Ticker or Trading Symbol
Boston Therapeutics, Inc. [BTHE]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last)
(First)
(Middle)
C/O BOSTON THERAPEUTICS, INC., 354 MERRIMACK STREET, #4
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2017
(Street)

LAWRENCE, MA 01843
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock (2) $ 0.1 08/14/2017   P   1,000,000   08/14/2017   (2) Common Stock 1,000,000 $ 0.1 1,000,000 D  
Common Stock Purchase Warrants (2) $ 0.15 08/14/2017   P   2,000,000   08/14/2017 08/14/2022 Common Stock 2,000,000 $ 0.15 2,000,000 D  
Series A Preferred Stock (2) $ 0.1 02/02/2018   P   1,000,000   02/02/2018   (2) Common Stock 1,000,000 $ 0.1 1,000,000 D  
Common Stock Purchase Warrants (2) $ 0.15 02/02/2018   P   2,000,000   02/02/2018 02/02/2023 Common Stock 2,000,000 $ 0.15 2,000,000 D  
Stock Options (1) $ 0.2             08/12/2016 08/12/2021 Common Stock 6,000,000   6,000,000 D  
Stock Options $ 0.18             03/25/2015 08/12/2026 Common Stock 500,000   500,000 D  
Stock Options $ 0.1             09/15/2011 08/12/2026 Common Stock 1,500,000   1,500,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
RAUSCH CARL W
C/O BOSTON THERAPEUTICS, INC.
354 MERRIMACK STREET, #4
LAWRENCE, MA 01843
  X     Chief Executive Officer  

Signatures

 /s/ Carl W. Rausch   02/12/2018
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The options vest in three equal tranches of 2,000,000 upon the Company the Company raising $1,000,000 in financing, the Company raising $5,000,000 in financing and the Company entering into a significant corporate alliance for substantial marketing and selling of the Company's product portfolio. The initial tranche is exercisable at $0.20 per share, the second tranche will be $0.40 per share and the third tranche will be $0.60 per share, which such vesting is subject to continued employment as an executive with the Company as of the vesting date. The expiration date is five years from the date of grant.
(2) On August 14, 2017 and February 2, 2018, World Technology East II Limited ("WTE") acquired 10,000 shares of Series A Preferred Stock and common stock purchase warrants to acquire 2,000,000 shares of common stock on each date. Mr. Rausch and Conroy Cheng each equally control WTE and share dispositive and voting control over such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.